Metropolis Healthcare, a leading diagnostics chain, is focusing on enhancing its presence in key regions by customising services for local markets. In FY22, Metropolis had set a target to expand its network by adding 90 laboratories and 2,000 service centres by FY25.
According to CEO, Surendran Chemmenkotil, the company remains on track, with 25 labs and 500 centres expected to be added in this financial year. This expansion increased the company’s footprint to around 700 towns in FY23, up from 300. "Most of the labs are coming in tier 2 and tier 3 cities," he said, adding "We plan to move to 1,000 towns by the end of the next fiscal year."
However, the next phase of growth will be driven primarily by inorganic expansion. Metropolis is actively seeking acquisitions, particularly in North India, to strengthen its regional presence.
Last quarter, the company announced its acquisition of Delhi-NCR-based Core Diagnostics. This move will expand its oncology portfolio and bolster its position in North India. The acquisition process will be completed in four to six weeks.
